Connection

DAVID POPLACK to Dose-Response Relationship, Drug

This is a "connection" page, showing publications DAVID POPLACK has written about Dose-Response Relationship, Drug.
  1. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
    View in: PubMed
    Score: 0.032
  2. Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. Biochem Pharmacol. 1993 Nov 02; 46(9):1627-36.
    View in: PubMed
    Score: 0.021
  3. Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst. 1993 Jun 16; 85(12):993-6.
    View in: PubMed
    Score: 0.020
  4. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501.
    View in: PubMed
    Score: 0.020
  5. Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst. 1992 Sep 02; 84(17):1332-5.
    View in: PubMed
    Score: 0.019
  6. Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res. 1992 Jun 15; 52(12):3503-5.
    View in: PubMed
    Score: 0.019
  7. Modulation of thiopurine cytotoxicity in the HL-60 cell line by physiological concentrations of hypoxanthine. Cancer Res. 1986 Dec; 46(12 Pt 1):6286-9.
    View in: PubMed
    Score: 0.013
  8. Experimental approaches to the treatment of CNS leukemia. Am J Pediatr Hematol Oncol. 1979; 1(2):141-9.
    View in: PubMed
    Score: 0.007
  9. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
    View in: PubMed
    Score: 0.007
  10. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995 May; 13(5):1238-41.
    View in: PubMed
    Score: 0.006
  11. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8.
    View in: PubMed
    Score: 0.005
  12. Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res. 1991 Jun 15; 51(12):3171-6.
    View in: PubMed
    Score: 0.004
  13. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res. 1990 Nov 15; 50(22):7226-31.
    View in: PubMed
    Score: 0.004
  14. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr. 1987; (5):207-12.
    View in: PubMed
    Score: 0.003
  15. Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep. 1984 Mar; 68(3):521-5.
    View in: PubMed
    Score: 0.003
  16. Inhibition of human lymphoproliferation by intravenous lipid emulsion. Clin Immunol Immunopathol. 1982 Nov; 25(2):196-202.
    View in: PubMed
    Score: 0.002
  17. "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978 May; 51(5):835-42.
    View in: PubMed
    Score: 0.002
  18. Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis. J Natl Cancer Inst. 1977 Jun; 58(6):1753-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.